Evaluation of maternal serum SERPINC1, E-selectin, P-selectin, RBP4 and PP13 levels in pregnancies complicated with preeclampsia

Palalıoğlu, Rabia Merve; Erbıyık, Halil İbrahim

doi:10.1080/14767058.2023.2183472

Cited by 5 publications

(3 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This was consistent with the findings of Mendola et al, who observed this association to be true of preterm but not of term PE [65]. Two further studies reported elevated RBP4 levels in PE [66,67], whereas five studies found no significant differences in RBP4 levels between PE and non-PE subjects [59,[68][69][70][71]. Nonetheless, Masuyama et al, described circulating maternal RBP4 to be significantly increased in overweight individuals with late-onset PE in comparison to overweight individuals with normotensive gestations and normal-weight individuals with late-onset PE [71].…”

Section: Rbp4 In Gdm and Pesupporting

confidence: 91%

Adipokines in Pregnancy: A Systematic Review of Clinical Data

et al. 2023

View full text Add to dashboard Cite

Adipokines are signaling proteins involved in metabolic, endocrinological, vascular and immunogenic processes. Associations of various adipokines with not only insulin resistance but also with increased insulin sensitivity, increased systolic blood pressure, and atherosclerosis highlight the significance of adipokines in several components of metabolic syndrome and metabolic diseases in general. As pregnancy presents a unique metabolic state, the role of adipokines in pregnancy, and even in various pregnancy complications, appears to be key to elucidating these metabolic processes. Many studies in recent years have attempted to clarify the role of adipokines in pregnancy and gestational pathologies. In this review, we aim to investigate the changes in maternal adipokine levels in physiological gestation, as well as the association of adipokines with pregnancy pathologies, such as gestational diabetes mellitus (GDM) and preeclampsia (PE). Furthermore, we will analyze the association of adipokines in both maternal serum and cord blood with parameters of intrauterine growth and various pregnancy outcomes.

show abstract

Section: Rbp4 In Gdm and Pesupporting

confidence: 91%

Adipokines in Pregnancy: A Systematic Review of Clinical Data

et al. 2023

View full text Add to dashboard Cite

show abstract

“…On the other hand, inhibitory proteases, such as APC, act as natural anticoagulants. This means that the homeostasis of the coagulation-fibrinolysis system is brought about by a balance of protease inhibitors and activators [ 32 ].…”

Section: Hemostasis and Its Regulationmentioning

confidence: 99%

“…Moreover, a series of protease inhibitors such as serine protease inhibitors (SERPIN) [ 32 ], including AT, heparin cofactor II, protein-Z-dependent protease inhibitors (ZPI), protease nexin 1, and the C1 inhibitor exerts a negative control of coagulation and fibrinolysis. Other non-SERPIN anticoagulants, such as TFPI, the chief inhibitor of the TF-FVIIa complex, also play a role [ 33 ].…”

Section: Hemostasis and Its Regulationmentioning

confidence: 99%

The Magic of Proteases: From a Procoagulant and Anticoagulant Factor V to an Equitable Treatment of Its Inherited Deficiency

Pablo-Moreno

Miguel-Batuecas

Sancha

et al. 2023

IJMS

View full text Add to dashboard Cite

Proteostasis, i.e., the homeostasis of proteins, responsible for ensuring protein turnover, is regulated by proteases, which also participate in the etiopathogenesis of multiple conditions. The magic of proteases is such that, in blood coagulation, one same molecule, such as coagulation factor V, for example, can perform both a procoagulant and an anticoagulant function as a result of the activity of proteases. However, this magic has an insidious side to it, as it may also prevent the completion of the clinical value chain of factor V deficiency. This value chain encompasses the discovery of knowledge, the transfer of this knowledge, and its translation to clinical practice. In the case of rare and ultra-rare diseases like factor V deficiency, this value chain has not been completed as the knowledge acquisition phase has dragged out over time, holding up the transfer of knowledge to clinical practice. The reason for this is related to the small number of patients afflicted with these conditions. As a result, new indications must be found to make the therapies cost-effective. In the case of factor V, significant research efforts have been directed at developing a recombinant factor V capable of resisting the action of the proteases capable of inactivating this factor. This is where bioethics and health equity considerations come into the equation.

show abstract